Zhifei Bio-Products secures patent for adenovirus vector preparation

Chongqing Zhifei Biological Products Co., Ltd. and its wholly-owned subsidiaries, Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. and Anhui Zhifei Longkema Biopharmaceutical Co., Ltd., announced the acquisition of an invention patent certificate. The patent, titled "A stable adenovirus vector lyophilized preparation and its application," was granted with patent number ZL202311377259.3.

The patent application was filed on October 24, 2023, and the authorization announcement date was December 5, 2025. This patent was obtained through the company's independent research and development process and is intended for future application in relevant R&D projects.

While the acquisition of this patent certificate is not expected to have a significant impact on the company's recent production and operations, it is beneficial for further enhancing its intellectual property protection system. This will allow the company to fully leverage its independent intellectual property advantages, promote technological innovation, and strengthen its core competitiveness.